Nucleic acids and corresponding proteins entitled 282p1g3 useful in treatment and detection of cancer

Abstract

A novel gene 282P1G3 and its encoded protein, and variants thereof, are described wherein 282P1G3 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 282P1G3 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 282P1G3 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 282P1G3 can be used in active or passive immunization.

1 . A method of delivering a cytotoxic agent to a cell that expresses a 282P1G3 protein comprising the amino acid sequence set forth in SEQ ID NO:3, said method comprising:
 providing the cytotoxic agent conjugated to an antibody or antigen-binding fragment thereof that binds specifically to the protein; and   exposing the cell to the antibody-agent or fragment-agent conjugate.   
     
     
         2 . The method of  claim 1 , wherein the antibody is a monoclonal antibody. 
     
     
         3 . The method of  claim 2 , wherein the monoclonal antibody is a humanized antibody. 
     
     
         4 . The method of  claim 2 , wherein the antigen-binding fragment is a Fab, F(ab□)2, or Fv fragment. 
     
     
         5 . The method of  claim 3 , wherein the antibody is a fully human antibody. 
     
     
         6 . The method of  claim 3 , wherein the antibody or antigen-binding fragment thereof comprises a murine antigen binding domain. 
     
     
         7 . The method of  claim 3 , wherein the antibody or antigen-binding fragment thereof is recombinantly produced. 
     
     
         8 . The method of  claim 1 , wherein the cytotoxic agent is selected from the group consisting of radioactive isotopes, chemotherapeutic agents and toxins. 
     
     
         9 . The method of  claim 8 , wherein the radioactive isotope comprises 212Bi, 131I, 131In, 90Y, 186Re, 211At, 125I, 188Re, 153Sm, 213Bi, 32P, or a radioactive isotope of Lu. 
     
     
         10 . The method of  claim 8 , wherein the chemotherapeutic agent is selected from the group consisting of taxol, topotecan, adriamycin, actinomycin, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, gelonin, and calicheamicin. 
     
     
         11 . The method of  claim 8 , wherein the toxin comprises ricin, ricin A chain, doxorubicin, daunorubicin, a maytansinoid, ethidium bromide, dihydroxy anthracin dione, diphtheria toxin,  Pseudomonas  exotoxin (PE) A, PE40, abrin, abrin A chain, modeccin A chain, alpha sarcin, mitogellin, retstrictocin, phenomycin, enomycin, curicin, crotin, sapaonaria officinalis inhibitor, glucocorticoid, auristatin, auromycin, yttrium, bismuth, combrestatin, duocarmycins, dolostatin, ccl 065, or cisplatin. 
     
     
         12 . The method of  claim 1 , wherein the antibody or antigen-binding fragment thereof further comprises a pharmaceutically acceptable carrier. 
     
     
         13 . The method of  claim 1 , wherein the cell is a cancer cell. 
     
     
         14 . The method of  claim 1 , wherein the cancer cell is from pancreas, ovary or lymph node. 
     
     
         15 . A method of inhibiting growth of a cell expressing a 282P1G3 protein comprising the amino acid sequence set forth in SEQ ID NO:3, comprising:
 exposing the cell to an effective amount of a cytotoxic agent conjugated to an antibody or antigen-binding fragment thereof that binds specifically to the protein of the cell,   whereby the growth of the cell is inhibited.   
     
     
         16 . The method of  claim 15 , wherein the antibody is a monoclonal antibody. 
     
     
         17 . The method of  claim 16 , wherein the monoclonal antibody is a humanized antibody. 
     
     
         18 . The method of  claim 16 , wherein the antigen-binding fragment is a Fab, F(ab□)2, or Fv fragment. 
     
     
         19 . The method of  claim 17 , wherein the antibody is a fully human antibody. 
     
     
         20 . The method of  claim 17 , wherein the antibody or antigen-binding fragment thereof comprises a murine antigen binding domain. 
     
     
         21 . The method of  claim 17 , wherein the antibody or antigen-binding fragment thereof is recombinantly produced. 
     
     
         22 . The method of  claim 15 , wherein the cytotoxic agent is selected from the group consisting of radioactive isotopes, chemotherapeutic agents and toxins. 
     
     
         23 . The method of  claim 22 , wherein the radioactive isotope comprises 212Bi, 131I, 131In, 90Y, 186Re, 211At, 125I, 188Re, 153Sm, 213Bi, 32P, or a radioactive isotope of Lu. 
     
     
         24 . The method of  claim 22 , wherein the chemotherapeutic agent is selected from the group consisting of taxol, topotecan, adriamycin, actinomycin, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, gelonin, and calicheamicin. 
     
     
         25 . The method of  claim 22 , wherein the toxin comprises ricin, ricin A chain, doxorubicin, daunorubicin, a maytansinoid, ethidium bromide, dihydroxy anthracin dione, diphtheria toxin,  Pseudomonas  exotoxin (PE) A, PE40, abrin, abrin A chain, modeccin A chain, alpha sarcin, mitogellin, retstrictocin, phenomycin, enomycin, curicin, crotin, sapaonaria officinalis inhibitor, glucocorticoid, auristatin, auromycin, yttrium, bismuth, combrestatin, duocarmycins, dolostatin, ccl 065, or cisplatin. 
     
     
         26 . The method of  claim 15 , wherein the antibody or antigen-binding fragment thereof further comprises a pharmaceutically acceptable carrier. 
     
     
         27 . The method of  claim 15 , wherein the cell is a cancer cell. 
     
     
         28 . The method of  claim 15 , wherein the cancer cell is from pancreas, ovary or lymph node.